Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mucin-22 (MUC22)
- Target
- MUC22
- Molecular classification
- Membrane-bound mucin (transmembrane glycoprotein), High-molecular-weight glycoprotein, Other
01
Overview
Mucin-22 (MUC22) is a membrane-bound, high-molecular-weight glycoprotein belonging to the mucin family, expressed mainly on epithelial surfaces in the respiratory tract and other mucosal tissues[2]. It plays a crucial role in maintaining the mucosal barrier, modulating epithelial cell signaling, and suppressing cell proliferation and migration[1][2]. In non-small cell lung cancer (NSCLC), epigenetic modifications such as DNA methylation regulate MUC22 expression, with decreased expression acting as a poor prognostic marker in squamous cell carcinoma and increased expression marking poor prognosis in adenocarcinoma. While not currently targeted by any approved drugs, MUC22 and its epigenetic regulation are under investigation for their potential as diagnostic, prognostic, and therapeutic biomarkers in cancer—especially in precision medicine for NSCLC subtyping and risk assessment[1][2].
- Other names
- Mucin-22MUC22G4PBMUCL1Panbronchiolitis-related mucin-like protein 1Panbronchiolitis related mucin-like 1
02
Mechanism of action
Epigenetic reactivation: Demethylating agents and histone deacetylase inhibitors can increase MUC22 expression by reducing promoter methylation and increasing histone acetylation[1].
03
Biological functions
Maintenance of mucosal barrier integrityReceptor/sensor for signal transduction on epithelial cellsInhibition of epithelial cell proliferation and motilityInvolvement in epithelial response to external stimuliOther
04
Disease associations
Cancer (especially lung cancer, including non-small cell lung carcinoma, lung adenocarcinoma, lung squamous cell carcinoma)Biomarker for molecular subtyping, prognosis, and epigenetic status in cancerPotential immune modulationOther
05
Safety considerations
No established safety concerns are reported for MUC22 as a therapeutic target due to the lack of selective drugs. However, mucin family proteins are critical for normal mucosal barrier function, so broad inhibition may risk compromising epithelial barriers and immune defense[2].
06
Interacting drugs
5-aza-2′-deoxycytidine (5-Aza)
1 more in the full profile.
07
Biomarkers
MUC22 expression and promoter methylation status serve as biomarkers for subtype stratification and prognosis in non-small cell lung carcinoma (NSCLC)[1].MUC22^Low^ and high methylation: Marker of squamous cell carcinoma (LUSC)MUC22^High^ and low methylation: Marker of adenocarcinoma (LUAD)Prognostic marker for patient survival in early-stage NSCLC[1].
Beyond the preview
Go deeper on Mucin-22 (MUC22).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mucin-22 (MUC22).